09:06 AM EDT, 04/10/2024 (MT Newswires) -- Certara ( CERT ) is poised to benefit from improving end markets, KeyBanc Capital Markets said in a note Tuesday.

KeyBanc said it increased its estimates for Certara ( CERT ) along with its "higher conviction of top-line trends based on commentary around improving biotech end markets from bio-simulation peers."

The firm raised its revenue estimate to $388.6 million from $387.1 million and adjusted EBITDA estimate to $123.6 million from $123.2 million for Certara ( CERT ) in 2024.

KeyBanc said it upgraded Certara ( CERT ) to overweight from sector weight, with a price target of $23.

The company's shares were up 1% in premarket activity on Wednesday.

Price: 18.7, Change: +0.19, Percent Change: +1.03